If you don't understand one of the words in this article, just double-click it.
A window will open with a definition from CancerWEB's On-line Medical Dictionary. If the double-click feature
doesn't work in your browser, you can enter the word below:
A team of researchers has identified how the anti-herpes drug acyclovir (Zovirax) limits HIV replication in people coinfected with herpes simplex virus (HSV), according to a report published in the September 11 issue of Cell Host & Microbe.
During the past 15 years, scientists have occasionally reported that people with HIV taking acyclovir for herpes also appear to have survival advantages and reductions in HIV levels, compared with people coinfected with both viruses not taking acyclovir. Until now, however, researchers doubted that acyclovir directly affected HIV replication. Rather, because acyclovir can reduce inflammation of the immune system by lowering herpes virus levels, experts assumed it also reduces the number active CD4 cells that can become targets of HIV infection.
Andrea Lisco, MD, PhD, from the National Institutes of Health in Bethesda, Maryland, and her colleagues suspected that acyclovir may actually have direct anti-HIV activity, at least within cells that are also infected with herpes viruses. Their suspicions were due to the way that acyclovir works.
For acyclovir to be incorporated into newly forming herpes viruses—thus stopping viral replication—it must first bind to phosphorus molecules with the help of a herpes virus enzyme called thymidine kinase. Dr. Lisco and her team theorized that acyclovir may act against HIV only once it has been bound to phosphorus molecules, a process called phosphorylation, which can only occur in herpes infected cells carrying the thymidine kinase enzyme.
Lisco’s team first studied acyclovir’s impact on HIV in cells that were infected or uninfected with herpes. They confirmed that HIV reproduction did decrease only in cells infected with herpes. Taking their experiments one step further, they added a laboratory version of acyclovir that was already phosphorylated. The phosphorylated acyclovir acted against HIV even in cells that weren’t coinfected with herpes.
The authors suggest that treating people infected with both HIV and herpes with both HIV treatments and acyclovir could diminish the likelihood of transmitting HIV—a conclusion that has been offered by other research teams. They also comment that further research should be conducted with various formulations of acyclovir to determine whether it may have a role in combination anti-HIV therapy.
Please click OK to confirm your comment and confirm you accept our posting rules. Note your message will be reviewed by our staff before going live.
Previous Comments:
comments 1 - 3 (of 3 total)
Finnboy, , 2008-09-17 14:54:10
vnsatyr,
Yes. Valaciclovir (the phosphorylated prodrug version of acyclovir) - because of the way it processed by the body, bypasses the herpes requirement for HIV suppression to occur. The research mentions this. Valaciclovir is still patented though.
Ben, Daytona Beach, FL, 2008-09-17 11:44:40
I have had some insurance issues, due to that there were a couple of periods when I did not have acyclovir, I discussed with my doctor about 2 years ago the fact that I get a bump to my t cells after restarting acyclovir. I only take Kaletra and acyclovir. T cells stay around 600, viral load about 75. HIV+ for 21 years.
vnsatyr, , 2008-09-17 11:09:08
Question, For those of us not co-infected with the Herpes Virus ,any of them, is there a way to attach the thymidine kinase enzyme to a normal, uninfected cell so that HIV could not go thru the phosphorylation step? Hence, not infecting a normal, healthy cell??? Can anyone get back to me on this? Thanks
vnsatyr
